Business
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact and strong commercial potential over the coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve blockbuster status or transform
About this update from Clarivate Plc
[{"type":"text","content":"Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact and strong commercial potential over the coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve blockbuster status or transform care within five years. Drugs to Watch has consistently identified therapies that redefine patient care, with over 110 featured to date, making it a central reference for tracking innovation in the pharmaceutical sector.","length":757,"tagName":"p"},{"type":"image","alt":"Clarivate logo","displaySize":"","headline":null,"caption":"Clarivate logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":127,"url":"https://media.zenfs.com/en/prnewswire.com/0ccf29bb19b6eae58105fdbb6b41514f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1UOZM6Hxg1qtBQRY71PEqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0ccf29bb19b6eae58105fdbb6b41514f","width":400,"height":127}}},{"type":"text","content":"Drawing on Clarivate integrated data assets and AI-powered intelligence, the report identifies emerging therapies that may achieve blockbuster status or drive meaningful transformation in patient care. The analysis reflects the interplay of scientific progress, regulatory change and evolving competitive dynamics as companies navigate increasingly complex global markets.","length":372,"tagName":"p"},{"type":"text","content":"Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "The pharmaceutical landscape in 2026 will be defined by both unprecedented innovation and increasing complexity. From metabolic disease to rare conditions and precision therapies, the ability to anticipate emerging drug trends and understand shifting patient and market dynamics will be critical. This year's Drugs to Watch report highlights not on...